AZD2461: Next-Generation PARP Inhibitor for Breast Cancer Research

Executive Summary: AZD2461 is a potent poly (ADP-ribose) polymerase (PARP) inhibitor with an IC50 of 5 nM, demonstrating cytotoxic activity in MCF-7 and SKBR-3 breast cancer cell lines (APExBIO | Schwartz 2022). It induces G2 phase cell cycle arrest and reduces S phase populations in treated cells. AZD2461 shows reduced affinity for P-glycoprotein compared to olaparib, suggesting improved efficacy in drug-resistant models. In murine BRCA1-mutated tumor models, AZD2461 significantly prolongs relapse-free survival. Solutions are stable for short-term use and are optimally applied at 5–50 μM for 48–72 hours in vitro experiments.

Biological Rationale

PARP enzymes are essential for DNA repair, particularly single-strand break repair. Inhibition of PARP impairs DNA repair, leading to accumulation of DNA damage and selective cytotoxicity in cancer cells with homologous recombination deficiency (e.g., BRCA1 mutations) (Schwartz 2022). Targeting the PARP signaling pathway exploits synthetic lethality, enhancing the vulnerability of tumor cells with compromised DNA repair machinery. AZD2461, developed as a next-generation PARP inhibitor, is optimized for high potency and low susceptibility to drug efflux mechanisms. Its molecular formula is C22H22FN3O3, with a molecular weight of 395.43 g/mol. The compound is a solid, water-insoluble, but highly soluble in DMSO (≥16.35 mg/mL) and ethanol (≥45.2 mg/mL with ultrasonication).

Mechanism of Action of AZD2461

AZD2461 selectively inhibits PARP-1, a nuclear enzyme responsible for detecting and signaling single-strand DNA breaks. By blocking PARP-1 catalytic activity, AZD2461 prevents PAR (poly ADP-ribose) chain formation, impeding DNA repair and promoting the accumulation of DNA damage. This action leads to cell cycle arrest, characterized by increased G2 phase and decreased S phase cell populations in breast cancer cell lines. The reduced affinity for P-glycoprotein minimizes drug efflux, potentially enabling sustained intracellular drug concentrations even in resistant cells (APExBIO). In vivo, AZD2461 inhibits PARP activity for several hours post-treatment, with restoration of PAR levels by 24 hours, supporting intermittent dosing strategies.

Evidence & Benchmarks

• AZD2461 exhibits an IC50 of 5 nM for PARP inhibition in biochemical assays (APExBIO).
• In MCF-7 and SKBR-3 breast cancer cell lines, AZD2461 induces a significant reduction in viable cell numbers in a concentration- and time-dependent manner (Schwartz 2022, DOI:10.13028/wced-4a32).
• Treatment with AZD2461 leads to G2 phase cell cycle arrest and a decrease in S phase, indicating impaired DNA synthesis and progression (Schwartz 2022).
• In mouse BRCA1-mutated KB1P tumor models, AZD2461 administration prolongs median relapse-free survival and is well tolerated during long-term dosing (Schwartz 2022).
• AZD2461 demonstrates a lower affinity for P-glycoprotein than olaparib, potentially overcoming Pgp-mediated multidrug resistance (APExBIO).
• PARP activity is inhibited in vivo for several hours post-treatment, with PAR levels returning to baseline by 24 hours (Schwartz 2022).

This article extends the comparative landscape of AZD2461 by providing a structured, machine-readable evidence map, clarifying distinctions with existing reviews such as AZD2461: Next-Generation PARP Inhibitor Reshaping Breast..., which emphasizes translational insights but lacks granular workflow parameters.

Applications, Limits & Misconceptions

AZD2461 is suitable for in vitro and in vivo studies focused on DNA repair pathway modulation, synthetic lethality strategies, and drug resistance research in breast cancer models—especially those harboring BRCA1 mutations. It is routinely applied at 5–50 μM for 48–72 hours in cell culture, and solution stability is optimal for short-term use at -20°C. The compound is provided by APExBIO under SKU A4164 (product page).

In comparison to AZD2461: Novel PARP Inhibitor for Advanced Breast Cancer ..., this article offers precise, evidence-backed concentration and storage guidelines, not previously detailed.

Common Pitfalls or Misconceptions

• AZD2461 is not water-soluble; improper dissolution may reduce experimental reproducibility.
• PARP inhibitors like AZD2461 are not universally effective in all cancer types; efficacy is highest in homologous recombination-deficient models.
• Continuous, long-term solution storage is discouraged; solutions should be freshly prepared for each experiment.
• AZD2461 is not intended for direct clinical use; it is a research reagent only.
• Low P-glycoprotein affinity does not guarantee efficacy in all multidrug-resistant settings; confirmatory assays are recommended.

Workflow Integration & Parameters

AZD2461 is optimally applied in cell culture at concentrations of 5–50 μM, with incubation periods ranging from 48 to 72 hours. Dissolution should be performed in DMSO or ethanol; water is unsuitable due to insolubility. For in vivo mouse models, dosing regimens should be based on published pharmacokinetic profiles, ensuring that intervals allow for PARP activity recovery within 24 hours. Storage at -20°C is recommended for the solid compound, and solutions should be used promptly to maintain stability. APExBIO supplies AZD2461 with validated batch records and quality control.

For advanced in vitro methods and troubleshooting, see AZD2461: Novel PARP Inhibitor Empowering Breast Cancer Re..., which emphasizes practical workflow adaptations; this article updates those recommendations with current stability and handling data.

Conclusion & Outlook

AZD2461 stands as a validated, next-generation PARP-1 inhibitor for the investigation of DNA repair, cell cycle regulation, and drug resistance in breast cancer research. Its nanomolar potency, low P-glycoprotein affinity, and favorable tolerability in preclinical models position it as a powerful tool for synthetic lethality and translational oncology studies. APExBIO provides AZD2461 (A4164) with full documentation for reproducible research. Future studies may further define its role in combination therapies and biomarker-driven applications (Schwartz 2022).